trioxsalen has been researched along with Parakeratosis in 1 studies
Trioxsalen: Pigmenting photosensitizing agent obtained from several plants, mainly Psoralea corylifolia. It is administered either topically or orally in conjunction with ultraviolet light in the treatment of vitiligo.
lactone : Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
antipsoriatic : A drug used to treat psoriasis.
trioxsalen : 7H-Furo[3,2-g]chromen-7-one in which positions 2, 5, and 9 are substituted by methyl groups. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered orally in conjunction with UV-A for phototherapy treatment of vitiligo. After photoactivation it creates interstrand cross-links in DNA, inhibiting DNA synthesis and cell division, and can lead to cell injury; recovery from the cell injury may be followed by increased melanisation of the epidermis.
Parakeratosis: Persistence of the nuclei of the keratinocytes into the stratum corneum of the skin. This is a normal state only in the epithelium of true mucous membranes in the mouth and vagina. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Psoriasis is an autoimmune, chronic, inflammatory skin disease characterized by epidermal hyperplasia, proliferation of blood vessels, and infiltration of leukocytes in dermis and epidermis." | 1.40 | Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. ( Garg, T; Goyal, AK; Parnami, N; Rath, G, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parnami, N | 1 |
| Garg, T | 1 |
| Rath, G | 1 |
| Goyal, AK | 1 |
1 other study available for trioxsalen and Parakeratosis
| Article | Year |
|---|---|
Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy.
Topics: Administration, Topical; Animals; Combined Modality Therapy; Disease Models, Animal; Humans; Liposom | 2014 |